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ABSTRACT
A male, 32 years of age, presented with dysuria and abdominal pain, but no gross
hematuria. He emigrated three years earlier from Somalia, East Africa, and was
currently employed as a poultry processor in a rural Wisconsin community. The
patient denied any trauma, sexual activity, or family history of significant illness.
Abdominal and genitourinary exams were normal with negative tests for
gonococcus and chlamydia. Urinalysis demonstrated microhematuria. A urogram
and retrograde pyelogram revealed a mildly dilated right ureter down to the
ureterovesical junction. Cystoscopy showed punctate white lesions on the bladder
urothelium. Ureteroscopy was used to biopsy abnormal tissue in the distal ureter
and bladder. Biopsy tissue demonstrated deposits of Schistosoma haematobium
eggs. No ova were seen in collected urine specimens. The patient was
successfully treated with praziquantel and will be monitored for sequelae of the
disease.
Schistosomiasis (Bilharziasis) can be expected to be seen with increasing
frequency in the United States with the continuing influx of immigrants and
refugees, as well as the return of travelers and soldiers from endemic areas. While
no intermediate snail host exists for the transmission of Schistosoma sp. in the
United States, the continued importation of exotic animals including snails from
Africa, as well as the ability of schistosomes to shift host species warrants
concern. Additionally, increasing disease associated with non-human bird
schistosomes of the same genus seen in the midwestern United States is
occurring throughout Europe. One should be aware that praziquantel may not
always be available or effective in the treatment of schistosomiasis. It behooves
the practicing clinician to remain updated on the status of this widespread
zoonosis.
INTRODUCTION
The population demographics of the United States are changing. As an example,
the population of political refugees within Wisconsin has risen from 30,000 in
1990 to more than 60,000 in 2002 and continues to increase.1 Most of these
refugees originate from Southeast Asia, Eastern Europe, and Africa. 
We present the case of a ureteral obstruction in a Somalian refugee caused by a
disease entity not commonly seen in the American Midwest. The case serves to
emphasize the importance of knowledge of tropical medicine, even in the
northern tier of the United States.
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CASE REPORT
A male, 32 years of age, presented with dysuria and
abdominal pain. He had no other gastrointestinal symptoms.
There had been no gross hematuria. The patient denied any
trauma or sexual activity. The patient had been treated at
another clinic with Rocephin® and oral antibiotics. Review
Figure 1. An intravenous urogram displays a mildly dilated
right ureter (arrow) down to the ureterovesical junction.
Figure 2. Retrograde pyelogram demonstrating irregularity in
the distal 2 cm of the right ureter.
Figure 3. Histopathology of the abnormal urinary tract tissue
obtained on ureteroscopy reveals Schistosoma haematobium
eggs with their characteristic terminal spine (arrow).
of symptoms was negative for any ophthalmic or
rheumatologic complaints. Family history was negative for
any significant illnesses. The patient was a non-smoker and
had been working at a poultry processing plant since
emigrating from Somalia 3 years ago. Physical exam
revealed a healthy male. Abdominal and genitourinary exam
were normal.
Urinalysis demonstrated 6 to 10 WBCs, trace leukocyte
esterase, microhematuria, and negative nitrates. A urine
culture was negative. Polymerase chain reaction (PCR)
testing was negative for gonococcus and chlamydia.
Because of the microscopic hematuria, an intravenous
urogram was obtained. Pertinent findings include a mildly
dilated right ureter down to the ureterovesical junction
(figure 1). A cystoscopic examination showed that the
bladder urothelium was dotted with punctate white lesions.
A retrograde pyelogram demonstrated irregularity in the
distal 2 cm of the right ureter (figure 2). Ureteroscopy
showed irregular, heaped-up tissue in the distal ureter. This
tissue, as well as the abnormal tissue in the bladder, was
biopsied. Pathologic examination of the biopsy tissue
showed classic bilharzial ova (figure 3). Collected urine was
not found to have any ova.
The patient was treated with praziquantel 20 mg/kg every 
6 hours for 1 day. He vomited with the first course of
praziquantel, losing some of the dose, so the course was
repeated. Approximately one month later symptoms of right
lower quadrant and flank pain had returned with sweating,
urinary frequency, and occasional urgency, likely the result
of infection and/or recurrence of ureteral stenosis that will
require further management after assessment by intravenous
urogram. He is also being monitored for sequelae of this
disease. 
A follow-up intravenous pyelogram was performed six
months after initial presentation and treatment. No evidence
of obstruction or filling defect was noted.
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DISCUSSION
Incidence
Schistosoma sp. infect 250 million people worldwide.2
Schistosomiasis (also called Bilharziasis after the German
tropical disease specialist, Theodore M. Bilharz, 1829-1862)
is second only to malaria in parasitic disease morbidity.
Approximately 500 to 600 million people in tropical and
subtropical countries are at risk, and of those infected, 120
million are symptomatic with 20 million having severe
manifestations.3 Schistosomiasis is endemic in many
countries, not only in sub-Saharan Africa, but the far East,
South and Central America, and the Caribbean.
Endemic distribution
Ten species of schistosomes can infect humans, but a vast
majority of infections are caused by Schistosoma mansoni,
S. japonicum, and S. haematobium.4 Of all people suffering
from schistosomiasis, 85% live in sub-Saharan Africa where
S. mansoni, S. haematobium, and S. intercalatum are
endemic.5,6 S. mansoni, S. intercalatum, and S. japonicum
largely cause hepatobiliary and gastrointestinal symptoms,
while S. haematobium causes urogenital symptoms.
Bilharziasis is endemic throughout Africa, but its
distribution is focal and constantly shifting as open
irrigation canals spread.7-9 The Bill and Melinda Gates
Foundation is funding a 4-year schistosomiasis control
initiative in Uganda, Tanzania, Zambia, Mali, Burkina Faso,
and Niger during which 15 million people will be treated.10
As recently as 2000, an article published in the New
England Journal of Medicine stated that schistosomiasis,
particularly S. haematobium, is not thought to occur in
Somalia.11 However, review of the tropical medicine
literature reveals that S. haematobium is endemic to Somalia
and presents a long-standing health problem there.9,12-19
Shifting demographics
In the United States, it is estimated that at least 400,000
individuals are infected. Most of these are immigrants, but
travelers including military, expatriates, and civilian
contractors have been infected as well.20-31 Southern Iraq is
an area endemic for S. haematobium, and it may be expected
that returning military personnel, while stationed there, may
have contracted infections upon exposure to fresh
water.27,32-35
Within the past decade, the United States has seen a large
influx of refugees from Somalia as a consequence of
continuing civil war.36,37 Minneapolis, Minnesota, is
believed to have the largest Somali immigrant population in
the United States with between 6,000 and 30,000 people
from that nation, most of whom arrived within the last 12
years.38 Initially placed by religious aid agencies,
Minnesota’s draw has been through available jobs and low
housing costs. In Somali refugee camps worldwide, the
word “Minneapolis” has come to symbolize a shot at the
American dream. Somalis who first located elsewhere in the
United States moved to the state because of the growing
community there, the decent cost of living, and good job
opportunities.
Lately, the slowing economy and housing shortages are
driving some of these refugees to Columbus, Ohio, which is
believed to have the second largest Somali immigrant
population in the country, estimated at 15,000. In
Milwaukee, there is a Somalian community of between 250
and 500 people. In Barron, Wisconsin, population of 3,000,
more than 300 Somalian immigrants have settled to work
year-round at a turkey processing plant.39,40 Further
increases in this population can be expected as the United
States opens its borders to close relatives of those already
here.41 Along with the influx of people, the manifestation of
diseases endemic to that part of the world can be expected to
be seen in the United States.
Life cycle
The life cycle and pathophysiology of S. haematobium has
been reviewed extensively in the literature.42 Briefly, when
eggs are excreted into fresh water, they hatch to release
motile, ciliated miracidia (embryos) that penetrate aquatic
bulinid snails, the intermediate host. Cercaria (larvae)
emerge from the snails and penetrate the skin of humans in
contact with the water (figure 4). The cercariae migrate to
the lungs and liver, and after 6 weeks, the mature worms
mate and migrate into the pelvic veins to begin oviposition.
The eggs penetrate small, thin-walled vessels in the
genitourinary system. During the active phase viable adult
worms deposit eggs that induce a granulomatous response
with the formation of polypoid lesions. During this phase
eggs are excreted. An inactive phase follows the death of the
adult worms.21 No viable eggs are present in the urine, and
large numbers of calcified eggs are present in the wall of the
bladder and other affected tissues. As fibrosis progresses,
polypoid patches flatten into finely granular patches.43
Symptomatic effects
A very vivid description of the symptomatic effects of S.
haematobium infection was provided in an early case report.
In 1944, Dr. Claude H. Barlow infected himself with
schistosomiasis in order to bring viable eggs to Johns
Hopkins University for study. He reported the consequences
of his voluntary infection with S. haematobium in 1949.44
His intense suffering is well described. In the early stages of
infection, cough, headache, loss of appetite, various aches
and pains, and often difficulty in breathing followed the
initial skin irritation. In more advanced infection, nausea
was common, accompanied by hematuria and in some cases
renal obstruction.
Clinical findings of hematuria, leukocyturia, urinary tract
complaints, tender abdomen, and supra-pubic tenderness are
associated with S. haematobium infections,45 but the clinical
outcome of infection is variable, ranging from mild symptoms
to chronic iron deficiency and anemia, to scarring and
deformity of the ureters and bladder, to chronic bacterial
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Figure 4. Eggs are eliminated with feces or urine 1 . Under optimal conditions the eggs hatch and release miracidia 2 , which
swim and penetrate specific snail intermediate hosts 3 . The stages in the snail include 2 generations of sporocysts 4 and the
production of cercariae 5 . Upon release from the snail, the infective cercariae swim, penetrate the skin of the human host 6 , and
shed their forked tail, becoming schistosomulae 7 . The schistosomulae migrate through several tissues and stages to their
residence in the veins ( 8 , 9 ). Adult worms in humans reside in the mesenteric venules in various locations, which at times seem
to be specific for each species 10 . For instance, S. japonicum is more frequently found in the superior mesenteric veins draining
the small intestine A , and S. mansoni occurs more often in the superior mesenteric veins draining the large intestine B .
However, both species can occupy either location, and they are capable of moving between sites, so it is not possible to state
unequivocally that one species only occurs in one location. S. haematobium most often occurs in the venous plexus of bladder C ,
but it can also be found in the rectal venules. The females (size 7 to 20 mm; males slightly smaller) deposit eggs in the small
venules of the portal and perivesical systems. The eggs are moved progressively toward the lumen of the intestine (S. mansoni
and S. japonicum) and of the bladder and ureters (S. haematobium), and are eliminated with feces or urine, respectively 1.
Pathology of S. mansoni and S. japonicum schistosomiasis includes: Katayama fever, hepatic perisinusoidal egg granulomas,
Symmers’ pipe stem periportal fibrosis, portal hypertension, and occasional embolic egg granulomas in the brain or spinal cord.
Pathology of S. haematobium schistosomiasis includes: hematuria, scarring, calcification, squamous cell carcinoma, and occasional
embolic egg granulomas in brain or spinal cord.
Human contact with water is thus necessary for infection by schistosomes. Various animals, such as dogs, cats, rodents, pigs,
horse and goats, serve as reservoirs for S. japonicum, and dogs for S. mekongi.
Geographic Distribution: 
Schistosoma mansoni is found in parts of South America and the Caribbean, Africa, and the Middle East; S. haematobium in
Africa and the Middle East; and S. japonicum in the Far East. Schistosoma mekongi and S. intercalatum are found focally in
Southeast Asia and central West Africa, respectively.
(Figure provided by Alexander J. da Silva and Melanie Moser for copyright-free dissemination through the Public Health Image
Library of the Centers for Disease Control and Prevention. Legend obtained through the Division of Parasitic Diseases, National
Center for Infectious Diseases, Centers for Disease Control and Prevention.)
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superinfection, to severe damage of urinary tract organs, and
ultimately to renal failure.46-50
Duration of infection
After maturing, schistosome worm pairs live in their
definitive host venous system and engage in egg-laying for
many years, even decades.51,52 This means that patients may
present with symptoms years after having immigrated from
or visited endemic regions.21 The eggs, rather than the adult
worms, play a crucial role in the pathogenesis of
schistosome infection.
Ureteral involvement
Obstructive uropathy is the most common and dangerous
complication of S. haematobium infection of the interstitial
and juxtavesicular portions of the ureter.21,24,53-56 Chronic
renal failure and immune-complex-mediated
glomerulonephritis may result.57-59 The urinary collecting
system, the ureters, bladder, seminal vesicles, prostate gland,
urethra, vas deferens, and testes may become involved.60,61
In the ureter, mostly the lower portion is affected because of
the blood supply anatomy. Eggs are found in all layers of the
ureter, and cause mural fibrosis, loss of the muscle layer,
and fibrosis. Stricture may occur.
Acute symptoms may include renal colic with pyelonephritis
and hydronephrosis.62 Long-standing obstruction may
present with silent obstruction or anuria. Most cases of
ureteral involvement also have bladder involvement.
Diagnosis
Diagnosis of urinary tract schistosomiasis is based on
history and clinical suspicion followed by laboratory studies.
These may include the enzyme-linked immunosorbent assay
(ELISA), serum antigens, and demonstration of ova in the
urine. Many cases are diagnosed by endoscopy and biopsy.
Traditionally for S. haematobium, microscopic examination
of urine and seminal fluids reveal eggs with characteristic
species-specific morphology.11,44,63,64 For best results, urine
collections should be made between 10:00 am and 2:00 pm
to ensure maximum yield.65 Another way to increase yield
of eggs in the urine is to have the patient go for a short run
or walk just before the urine is passed to facilitate the
shedding of the eggs from the bladder mucosa.29 Samples
may be centrifuged or filtered on membranes to enhance the
chances of finding eggs.66-68
Detection of eggs in stool samples is typically used in the
diagnosis of S. mansoni,69 but S. haematobium eggs may
also occasionally be found in the stool. Egg production can
be low and sporadic so the risk of missing the diagnosis by
egg detection alone is high.45
Ultrasonography has been used as a diagnostic technique for
assessment of urinary tract morbidity.49,50,70-73 Bladder
pathology can include thickening, the presence of polyps, or
the existence of masses protruding into the lumen. Kidney
dilation may occur unilaterally or bilaterally. Urograms can
reveal filling defects.22
Cystoscopic examination generally reveals masses and/or
punctuate white calcifications without ulceration or necrosis.
Similar lesions are seen in the uterus upon pelviscopic
examination when the reproductive tract is involved.21
Urinary eosinophil cationic protein has been shown to
correlate well with the extent of bladder pathology in 
S. haematobium infections.74
Immunodiagnostic assays have been developed to detect
circulating antibodies to semi-purified or fractionated
antigens75-81 and parasite circulating antigens in different
host body fluids.82-88 Falcon assay screening test 
(FAST)-ELISA and immunoblot assays for specific
antibodies to S. mansoni and S. haematobium adult worm
microsomal antigens are highly specific for both 
species.89,90 However, positive results in antibody assays do
not necessarily correlate with the worm burden, as measured
by egg output. Also, it is not possible to distinguish previous
exposure from current infections or reinfections.45,91-93 A
PCR method has been developed as a highly sensitive and
specific technique to detect Schistosoma sp. DNA.94
Medical treatment
Until the late 1970s, fouadin, a trivalent antimony
preparation, and potassium antimony tartrate were the only
treatments available, and the cure involved suffering more
intense than that caused by the disease.44 Metrifonate
(Trichlorfon: CASRN: 52-68-6) has been used for the
treatment of S. haematobium,15,16,95 but it has some severe
human neurological side effects.96
Currently, medical management of bilharziasis relies on
praziquantel, sometimes in combination with oxamniquine.
Praziquantel (Biltricide®, Bayer AG, Germany) a
heterocyclic prazino-isoquinoline, is highly effective against
all species of schistosomes pathogenic to humans.97,98
However, since its first use, praziquantel treatment has been
noted not to be 100% effective in eliminating S. haematobium
infection.99 In adult schistosomes, praziquantel induces
vesication, vacuolization, and disintegration of the
tegument.100-104 It also causes mature schistosome eggs to
hatch.105,106 Immature eggs remain unaffected and continue
to develop to maturity.107 In longitudinal studies, bladder
wall pathology and hydronephrosis have been found to
regress upon treatment, especially in active phases of the
infection.24,108,109 However, if chronic stricture of the ureters
has occurred, no significant reduction of the renal collecting
system may result.110 In such a case, surgical intervention
including mechanical dilation, resection, re-implantation,
formation of an ileal ureter, and even nephroureterectomy
may be required.24
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Drug availability
It behooves the medical community to keep the continuing
needs for such drugs in their collective consciousness. Not
long ago, Bayer Corporation Pharmaceutical Division had
decided to withdraw praziquantel from the United States
market for lack of sales. A campaign of letters, faxed
messages, and telephone calls from members of the
American Society of Tropical Medicine and Hygiene, the
International Society of Travel Medicine, and the Infectious
Disease Society of America served to increase the corporate
awareness of the unique role for this drug in the treatment of
immigrants, refugees, and returned travelers.111 As a
consequence, Bayer reversed its earlier discontinuation
decision, and therefore praziquantel was available for
treatment of the present case. With the vagaries of the
current climate of global drug import, export and reimport,
it is difficult to predict, however, whether this will always be
the case.112-114
Drug resistance
Another concern with respect to the future of praziquantel
treatment is the ever-present worry over the emergence of
drug resistance.115 Praziquantel has been in use for almost
25 years, during which time it has been the drug of choice
for many human and veterinary parasitic infections
worldwide.116-118 The European Commission has established
an International Initiative on Praziquantel Use to review
reports of low efficacy in clinical trials in Senegal and
Egypt, and reports of resistant S. mansoni strains isolated in
the laboratory.115,119-129 While investigations suggest that no
emergence of praziquantel resistance in S. haematobium has
yet occurred, mathematical models predict that such
resistance can be expected to occur as soon as 2010.130 As a
consequence new drugs are being actively
investigated.131,132
Adverse reactions
In healthy, uninfected humans, clinical trials showed no
clinically relevant drug-related changes.133,134 However, in
humans infected with S. mansoni or S. japonicum,
abdominal pain, nausea, vomiting, anorexia, diarrhea, and
bloody stools have been reported.135-138 These symptoms
occur immediately after treatment and are correlated with
the intensity of infection, suggesting an anaphylactic
response due to parasite and egg antigens released in
response to praziquantel.
In S. japonicum-infected mice, intestinal mast cells infiltrate
into the intestine. When praziquantel is administered by
injection, mature eggs hatch and the mast cells are activated
to release histamine and other biogenic amines. This mast
cell response plays a pivotal role in the pathogenesis of 
post-praziquantel anaphylactic signs. Additionally, antigenic
components from the hatched eggs, rather than from adult
worms play a major role as allergens in the pathogenesis of
adverse effects in praziquantel-treated mice.139
Severe symptoms occur more frequently in patients given
high dosages of praziquantel than in those given relatively
low, divided dosages.137 Thus, while single doses are more
convenient, treatment with two or more praziquantel
administrations, each at a low dosage, may reduce antigen
release, and has been suggested as a way to minimize the
occurrence of severe adverse effects.139
Vaccines
No effective vaccine is yet available against any of the
Schistosoma species. However, this may soon change. The
Schistosoma Genome Project, created in 1992, has begun to
yield comprehensive understanding of the molecular
mechanism involved in schistosome nutrition and
metabolism, host-dependent development and maturation,
immune evasion, and invertebrate evolution.2,140 New
potential vaccine candidates and drug targets are
emerging.141-146
Co-infection
It is also important to be aware that persons infected with 
S. haematobium can be simultaneously infected with S. mansoni
and other geohelminths.50,147-149 Evidence also suggests that
the type 2 immunological response (interleukin (IL)-4 and
IL-5) induced by S. haematobium may weaken the type 1
response (interferon-γ) making individuals more susceptible
to mycobacterial infections.150
Other potential sequelae
Secondary bacterial infection is common in
schistosomiasis.151 S. haematobium infections can not only
affect the urinary tract, but also other organs of the pelvic
floor, especially the reproductive organs, including the
prostate and scrotum,44 and the uterus and fallopian tubes,
which can lead to infertility.21,152-155 The vulva, vagina, and
cervix are affected more commonly than the internal pelvic
organs.156 Genital schistosomiasis may increase the risk of
human immunodeficiency virus (HIV) and human
papillomavirus (HPV) infection.157 S. haematobium can also
rarely infect the pericardium, central nervous system,
synovium, adrenal gland, thyroid gland and other
organs.24,54,158 S. haematobium infection has been
associated with squamous cell carcinoma, the only form of
bladder cancer with a parasitologic etiology.159-163
Potential threats to public health in the United States
The intermediate host for S. haematobium is the aquatic
snail Bulinus abyssinicus. Human transmission of S.
haematobium to countries where other susceptible bulinid
snails occur is of concern.164 B. abyssinicus is not present in
the United States. Studies have long been undertaken to
determine the potential of snails endemic to the United
States to transmit schistosomes, and none have thus far
proven capable of serving as a vector.44,165,166 However, it is
evident that snail host shifts have played a role in the
Schistosoma evolution, so the possibility of an emerging
competent schistosome/snail host combination in the United
States, while negligible, is present.167
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There is a North American schistosome of which one should
be aware, however, and that is the bird schistosome
(Trichobilharzia ocellata = T. szidati) that causes cercarial
dermatitis (swimmer’s itch).168-170 This causes initial
symptoms very similar to Schistosoma sp. infections when
the worm enters the skin. Thus far it is found primarily in
the upper Midwest, but has also been found in other regions
of the United States.171 The transmission of human zoonoses
via migratory birds is a growing concern in this area.172
The related schistosomes, T. franki and T. regent, are now
also spreading via bird vectors throughout Europe and are
becoming an emerging zoonoses there.173-175 In some cases,
it causes fever, respiratory and digestive allergic symptoms.
Great concern is being expressed over the possibility of
central nervous system involvement as well.176-179 Rodents
are being found to be capable intermediate hosts and might
be expected to be capable hosts of T. ocellata (T. szidati) in
the United States as well.
Another concern is not only the importation of the
schistosome from immigrants and travelers, but also the
importation of African snails into the country. Recent events
have vividly demonstrated that the importation of African
plants and animals into this country have caused public
health and agricultural concerns in the Midwest, as
exemplified by the monkeypox outbreak resulting from the
importation of the Giant Gambian Rat in 2003 and giant
African snails in 2004.180-182
Helminthic infections, dengue, leishmaniasis, African
trypanosomiasis, malaria, diarrheal diseases, and
tuberculosis are reemerging in Africa due to inadequate
intervention and control strategies.183 All of these need to be
considered as potential diseases in African immigrants and
travelers.
Another large immigrant population in Wisconsin are the
Hmong from Laos.184,185 Nearly 20,000 Hmong immigrated
to Wisconsin in the 1970s.186 A schistosome similar to 
S. japonicum, but endemic to a defined area of the Mekong
River in Laos and Cambodia is S. mekongi, and it has been
reported among the Hmong.187,188 It is characteristically
associated with hepatosplenic disease, but has also been
reported to involve the brain.189
CONCLUSION
While the Centers for Disease Control is developing a
strategy for better health assessments of refugees from areas
rife with endemic parasitic diseases of public health
significance, the chronic nature of schistosomiasis makes it
difficult to catch and treat all cases.19 This means that all
practitioners, but especially those in communities with large
and growing immigrant populations, need to increase
awareness of these diseases. Bilharziasis, although a
common disease, is rarely seen in Wisconsin. The diagnosis
is straight forward, if suspected, and effective, safe treatment
exists at the present time.
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